Natriuretic Peptide Receptor (NPR)

Natriuretic peptide receptor (NPR) ligands act on the receptors that mediate natriuresis and vasodilation. Atrial, B-type and C-type natriuretic peptides (ANP, BNP, CNP) bind three receptors, NPR-A, NPR-B and NPR-C. NPR-A and NPR-B are transmembrane guanylyl cyclases that make cyclic guanosine monophosphate (cGMP) rather than coupling to G proteins. A membrane guanylyl cyclase was shown in 1989 to act as an ANP receptor. NPR-C lacks a cyclase domain and was proposed in 1987 to clear natriuretic peptides from the circulation. Nesiritide acetate, a form of human BNP, and ularitide activate NPR-A. AP 811 is an NPR-C antagonist, and A 71915 is listed as an ANP antagonist.

2 Items

  • AP 811
    Cat. No.
    A61955

    AP 811

    AP 811 is a selective antagonist of the natriuretic peptide clearance receptor (NPR3) with a binding affinity (Ki) of 0.48 nM. It demonstrates over 20,000-fold selectivity for NPR3 compared to NPR1. AP 811 effectively inhibits atrial natriuretic peptide (ANP)-induced stimulation of transport pumps, making it a valuable tool for research into cardiovascular and kidney function regulation.

    1 mg
    $225.00
    5 mg
    $490.00
    All 3 sizes
  • A 71915
    Cat. No.
    A61956

    A 71915

    A 71915 is a potent and competitive antagonist of the natriuretic peptide receptor A (NPRA), exhibiting a pKi value of 9.18. It effectively displaces [125I]ANP in a dose-dependent manner, with a dissociation constant (Ki) of 0.65 nM. In cellular assays, A 71915 demonstrates a significant inhibition of rat ANP-induced cGMP production in NB-OK-1 cells, making it a valuable tool for research into cardiovascular signaling pathways and related therapeutic applications.

    1 mg
    $145.00
    5 mg
    $395.00
    All 2 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...